Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06502977
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-09
Brief Title:
Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Phase 2a Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of Tarlatamab in Chinese Subjects With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment DeLLphi-307
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
DeLLphi-307
Brief Summary:
The primary aim of this study is to evaluate the efficacy of tarlatamab as assessed by objective response rate ORR based on blinded independent central review BICR per Response Evaluation Criteria in Solid Tumors version 11 RECIST 11
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None